http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 10 Mar 2026 07:30:44 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Soligenix+receives+UK+medicine+designation+for+Behcet%27s+disease+drug/26135362.html <p>Soligenix Inc. (NASDAQ: SNGX) announced that its drug SGX945 has received Promising Innovative Medicine designation from the UK Medicines and Healthcare Products Regulatory Agency for treating Behçet's Disease.</p><p>The designation represents the first step toward potential inclusion in the UK Early Access to Medicines Scheme, which allows patients with life-threatening conditions to access experimental treatments before standard approval. The MHRA grants this designation to medicines that meet three criteria: addressing conditions with high unmet medical need, offering major advantages over current treatments, and demonstrating benefits that likely outweigh potential risks.</p><p>"We are excited that the MHRA agrees that dusquetide meets the specified http://www.streetinsider.com/Corporate+News/Soligenix+receives+UK+medicine+designation+for+Behcet%27s+disease+drug/26135362.html Tue, 10 Mar 2026 07:30:44 -0400 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/PRNewswire/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/PRNewswire/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/PRNewswire/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/PRNewswire/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/PRNewswire/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX http://www.streetinsider.com/PRNewswire/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>March 10, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4636815-1&amp;h=2165986885&amp;u=https%3A%2F%2Fwww.soligenix.com%2F&amp;a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that SGX945 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location> (<location value="LC/gb" idsrc="xmltag.org" >UK</location>) by the <span value="ACORN:3980789548" idsrc="xmltag.org" >Medicines and Healthcare Products Regulatory Agency</span> (MHRA) for the treatment of Behçet's Disease.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Soligenix+Announces+SGX945+Receives+Promising+Innovative+Medicine+Designation+from+the+UK+Medicines+and+Healthcare+Products+Regulatory+Agency/26135349.html Tue, 10 Mar 2026 07:30:00 -0400 A.01316444 A.13522767 A.29922014 A.31066700 A.39807895 A.50210954 A.50213784 A.60012002 O.00651740 O.01274156 O.01584314 O.03289173 O.08407916 O.22422661 O.42081221 O.49194046 O.69857460 SNGX